High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients

Oncologist

Volumn 17, Issue 6, 2012, Pages 766-774

  Bartholomeusz, Chandra ^a   Gonzalez Angulo, Ana M ^a   Liu, Ping ^a   Hayashi, Naoki ^a   Lluch, Ana ^b   Ferrer Lozano, Jaime ^b   Hortob́agyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

ERK; PEA 15; RPPA; Survival; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHOPROTEIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P27; TUBERIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEATH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84862857118     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0377     Document Type: Article

References (34)

1. Petrelli F, Cabiddu M, GhilardiMet al. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: Empiricism or evidence-based? Expert Opin Investig Drugs 2009;18:1467-1477.
2. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol 2008;26:2568-2581.
3. Corkery B, Crown J, Clynes M et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009;5:862-867.
4. Eralp Y, Derin D, Ozluk Y et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 2008;19:669-674.
5. Umemura S, Yoshida S, Ohta Y et al. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 2007;98:1889-1892.
6. McCawley LJ, Li S, Wattenberg EV et al. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 1999;274:4347-4353.
7. Adeyinka A, Nui Y, Cherlet T et al. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002;8:1747-1753.
8. Bartholomeusz C, Itamochi H, Nitta M et al. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 2006;25:79-90.
9. Formstecher E, Ramos JW, FauquetMet al. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell 2001;1:239-250.
10. Hill JM, Vaidyanathan H, Ramos JW et al. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain. EMBO J 2002;21:6494-6504.
11. Whitehurst AW, Robinson FL, Moore MS et al. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. J Biol Chem 2004;279:12840-12847.
12. Ramos JW, Kojima TK, Hughes PE et al. The death effector domain of PEA-15 is involved in its regulation of integrin activation. J Biol Chem 1998;273:33897-33900.
13. Ramos JW, Hughes PE, RenshawMWet al. Death effector domain protein PEA-15 potentiates Ras activation of extracellular signal receptor-activated kinase by an adhesion-independent mechanism. Mol Biol Cell 2000;11:2863-2872.
14. Chou FL, Hill JM, Hsieh JC et al. PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. J Biol Chem 2003;278:52587-52597.
15. Trencia A, Perfetti A, Cassese A et al. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol Cell Biol 2003;23: 4511-4521.
16. Krueger J, Chou FL, Glading A et al. Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signal-regulated kinasedependent transcription and cell proliferation. Mol Biol Cell 2005;16:3552-3561.
17. Glading A, Koziol JA, Krueger J et al. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 2007;67:1536-1544.
18. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A et al. PEA-15 inhibits tumorigenesis in an MDAMB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 2010;16:1802-1811.
19. Ma L, Chen Z, Erdjument-Bromage H et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-193.
20. Rivard N, Boucher MJ, Asselin C et al. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 1999;277:C652-C664.
21. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15:2472-2478.
22. Gee JM, Robertson JF, Ellis IO et al. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001;95:247-254.
23. McClelland RA, Barrow D, Madden TA et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001;142:2776-2788.
24. Mueller H, Flury N, Eppenberger-Castori S et al. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000;89:384-388.
25. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
26. Stephens P, Hunter C, Bignell G et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-526.
27. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogenactivated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 2001;60:290-301.
28. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000;275:38953-38956.
29. Murayama T, Inokuchi M, Takagi Y et al. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 2009;100:782-788.
30. Haling JR, Wang F, Ginsberg MH. Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) reprograms growth factor signaling by inhibiting threonine phosphorylation of fibroblast receptor substrate 2_. Mol Biol Cell 2010;21:664-673.
31. Bartholomeusz C, Rosen D, Wei C et al. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 2008;15;68:9302-9310.
32. Araujo H, Danziger N, Cordier J et al. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J Biol Chem 1993;268:5911-5920.
33. Estellés A, Charlton CA, Blau HM. The phosphoprotein protein PEA-15 inhibits Fas-but increases TNFR1-mediated caspase-8 activity and apoptosis. Dev Biol 1999;216:16-28.
34. Ripple MO, Kalmadi S, Eastman A. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/ extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival Breast Cancer Res Treat 2005;93:177-188.